Table 4.
Univariate Cox proportional hazard analysis of prognostic covariates in 257 patients with OSCC regarding disease-free survival and overall survival.
| Disease-Free Survival | Overall Survival | |||
|---|---|---|---|---|
| Characteristic | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Age (yrs) | ||||
| <50 | 1 | 1 | ||
| > = 50 | 0.901 (0.641–1.265) | 0.55 | 1.198 (0.883–1.626) | 0.25 |
| Tumor differentiation | ||||
| Well differentiated | 1 | 1 | ||
| Moderately/poorly differentiated | 1.282 (0.903–1.821) | 0.17 | 1.258 (0.915–1.729) | 0.16 |
| Primary tumor status | ||||
| T1/T2 | 1 | 1 | ||
| T3/T4 | 1.104 (0.788–1.546) | 0.57 | 1.487 (1.092–2.025) | 0.01 |
| Lymph node status | ||||
| LNM a−, ECS b− | 1 | 1 | ||
| LNM+, ECS− | 1.256 (0.777–2.030) | 0.35 | 1.643 (1.083–2.493) | 0.02 |
| LNM+, ECS+ | 2.354 (1.621–3.420) | <0.01 | 2.360 (1.673–3.329) | <0.01 |
| EGFR copy number | ||||
| Disomy | 1 | 1 | ||
| Polysomy | 1.160 (0.682–1.973) | 0.58 | 1.358 (0.819–2.253) | 0.24 |
| Amplification | 1.231 (0.802–1.891) | 0.34 | 1.264 (0.827–1.931) | 0.28 |
| CCND1 copy number | ||||
| Neutral | 1 | 1 | ||
| Amplification | 1.402 (0.998–1.971) | 0.05 | 1.485 (1.091–2.021) | 0.01 |
| EGFR and CCND1 CN status | ||||
| EGFR disomy/CCND1 copy neutral | 1 | 1 | ||
| Others | 1.332 (0.905–1.961) | 0.15 | 1.368 (0.926–2.022) | 0.12 |
| EGFR CNAs c and CCND1 amplification | 1.501 (0.960–2.347) | 0.08 | 1.750 (1.126–2.719) | 0.01 |
a LNM: lymph node metastasis; b ECS: extra-capsular spread; c Subgroup of EGFR CNAs contains EGFR polysomy or amplification OSCC cases.